At Surgical Aesthetics 411, we know filler science is more than skin deep. A new study connects the dots between volumetric behavior on 3D scans and how patients actually feel about their results weeks after treatment, arming injectors with a new toolset that can quantify how HA fillers behave over time while also predicting what patients perceive as success. If you’ve relied mostly on clinical experience and patient feedback to evaluate filler performance, this data-driven analysis offers a new dimension, quite literally.
New Metrics: TDF and EV
The study, a prospective led by Dr. Ivona Percec at the University of Pennsylvania and published in Plastic and Reconstructive Surgery, introduces two key volumetric markers: Tissue Displacement Factor (TDF) and Effective Volume (EV). Let’s break it down:
- TDF measures how much volume a given amount of HA displaces immediately post-injection. It’s a reflection of product lift and tissue response.
- EV is the volume that remains after the resolution of acute swelling and inflammation, essentially the “true” clinical volume at two weeks.
These markers allow for standardized evaluation of filler performance across regions, products, and patient types. For example, Restylane Lyft showed the highest TDF (1.25), followed by Restylane-L (1.14), while Restylane Silk, used in the lips, had a notably lower TDF (0.56).
Where Volume Goes (And Where It Doesn’t Stay)
Volume retention varied significantly by region. At 12 weeks, volume maintenance was:
- 79% in the midface (Restylane Lyft)
- 63% upper perioral
- 54% lower perioral and jawline
- 37% in the lips (Restylane Silk)
These numbers reflect what many injectors already observe: Mimetic areas lose volume faster. In the lips, lower retention may be attributed to high mobility, shallow injection planes, and inflammatory response to smaller particle HA. This quantitative confirmation can now support more specific counseling and product selection strategies.
3D Imaging: More Than a Marketing Tool
Using the Vectra M3 3D stereophotogrammetry system, researchers were able to precisely measure volume changes at multiple time points up to 12 weeks. The method validated that two-week volume reflects the final effective clinical volume, a useful standard when planning touch-ups or assessing longevity.
Notably, 3D image registration had an 88% success rate at 2 weeks but dropped to 40% at 12 weeks, largely due to pandemic-era limitations. Despite this, patient-reported outcomes were consistently high, with sustained improvements across multiple FACE-Q domains, including satisfaction with appearance, cheekbones, lips, and psychological and social functioning.
What Predicts Patient Satisfaction and Volume Loss
Age was a significant predictor of volume loss, particularly in mimetic zones, likely due to structural changes in fat compartment support and increased muscular dynamics. Higher BMI was associated with higher satisfaction, especially in lips, cheeks, and lower face, which could reflect both volumetric needs and patient expectations.
Interestingly, older patients reported greater satisfaction in several areas despite greater volume loss. This disconnect highlights the value of validated patient-reported outcome tools in parallel with objective imaging.
Clinical Takeaways
Here’s what you can apply to your injectable practice today based on the study findings:
- Expect different results in different zones. HA fillers behave uniquely in each facial area. High-volume areas like the midface retain more volume than dynamic zones like the lips.
- Incorporate TDF and EV into your treatment planning. These metrics offer a reproducible way to measure filler behavior across patients and products. Over time, this data could help refine dosing and selection protocols.
- Use 3D imaging to build patient trust. Visualizing before-and-after volume change, particularly at the two-week mark, can help set more realistic expectations and validate outcomes.
- Factor in patient-specific variables. Age and BMI influence both volume retention and perceived satisfaction. A one-size-fits-all approach to filler dosing will always fall short.
This study moves HA filler treatment closer to precision medicine. By aligning objective tissue behavior with patient satisfaction data, it enables more predictable, personalized outcomes. If you’re not yet leveraging volumetric imaging or standardized metrics like TDF and EV, now’s the time to integrate them into your injectable practice. Whether you’re optimizing product selection or managing patient expectations, these findings offer clear, measurable tools to elevate injectable outcomes at your practice.
SOURCES: Plastic and Reconstructive Surgery
This content is intended for educational purposes only and does not substitute for clinical judgment. Treatment decisions should be based on individual patient needs, professional guidelines, and a comprehensive clinical evaluation.
